GlassScriptPhysician profile
Oana L Andreescu
NPI 1306821947
$10,230.03
in general payments reported to CMS, 2019-2025
41 companies · $1,385 in 2025
The $1,385 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,704 · 2020: $1,471 · 2021: $1,451 · 2022: $1,522 · 2023: $1,553 · 2024: $1,145 · 2025: $1,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,105.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,301.57 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $690.26 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $637.81 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $555.55 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $501.00 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $487.49 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $393.40 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Astellas Pharma US INC | $361.74 | 2019-2024 | Veozah, Myrbetriq |
| Amgen INC. | $312.91 | 2019-2025 | Repatha, Otezla, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $290.81 | 2021-2025 | |
| Abbott Laboratories | $289.53 | 2019-2025 | Freestyle Libre 3 |
| Merck Sharp & Dohme LLC | $257.91 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Novartis Pharmaceuticals Corporation | $252.37 | 2019-2022 | |
| Amarin Pharma, INC. | $233.32 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oana Andreescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.